Table 1 Summary of progress and condition over time.
| Year | Age | ESR (mm/h) | Visual acuity | Disease activity* | Optic nerve head swelling | Systemic disease ‐ active polyarthropathy† | Systemic immunosuppressive agents | |||
|---|---|---|---|---|---|---|---|---|---|---|
| OD | OS | OD | OS | OD | OS | |||||
| 1999 | 1 | NA | NA | Y (Hypopyon) | Y | NA | Y | Ibuprofen | ||
| 2002 | 4 | NA | NA | Y | Y | NA | Y | MTX 15 mg/week, prednisolone 5 mg od, intermittent courses of IVMP 6‐8 weekly, ibuprofen 200 mg 3 times daily | ||
| 2003 | 5 | 45 | 6/6 | 6/6 | Y | Y | Y | Y | Y | Etanercept 0.4 mg twice/week, MTX 15 mg/week, prednisolone 5 mg od, ibuprofen 200 mg three times daily |
| 2004 | 6 | 58 | 6/12 | 6/12 | Y | Y | Y | Y | Y | Etanercept 0.5 mg twice/week, MTX 15 mg/wk, prednisolone 5 mg od |
| 2005 | 7 | 50 | 6/9 | 6/12 | Y | Y | Y | Y | Y | Stopped etanercept, anakinra 1 mg/kg/day, MTX 12.5 mg/week, prednisolone 5 mg od with slow taper |
| 2006 | 8 | 21 | 6/9 | 6/18 | N | N | N | N | N | Anakinra 1 mg/kg/day, MTX 12.5 mg/week |
ESR, erythrocyte sedimentation rate; IVMP, intravenous pulses of methylprednisolone; MTX, methotrexate; N, no; NA, information not available; Y, yes.
*Activity defined as per Standardisation of Uveitis Nomenclature guideline with respect to vitritis11,12.
†Polyarthropathy was the main systemic feature of activity.